Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Northsea Therapeutics B.V.
Headquarters: Amsterdam, Netherlands
Website: http://www.northseatherapeu...
Year Founded: 2017
Status: Private
BioCentury | Feb 20, 2025
Management Tracks
Hilberdink becomes president, U.S. human pharma at Boehringer
Plus: Nisa Leung leaves Qiming, and updates from Northsea, Ventus, Arima and Gate
BioCentury | Nov 10, 2023
Product Development
NorthSea pivots to diabetic NASH patients on Phase IIb icosabutate data
Misses primary non-alcoholic steatohepatitis resolution endpoint in all comers, but hits in Type II diabetes subgroup
BioCentury | Dec 17, 2021
Finance
Eyeing Phase III plan, NASH company NorthSea raises $80M
Ysios, Forbion among VCs backing NorthSea’s pipeline of engineered fatty acids for NASH, other disorders
BioCentury | Jun 24, 2020
Finance
Expect more company creation by BGV with its €105M fourth fund
Dutch VC BioGeneration Ventures expects to create half of the European start-ups backed by new fund
BioCentury | Jan 10, 2020
Emerging Company Profile
NorthSea: Engineering fatty acids for NASH
NorthSea’s structurally engineered fatty acids hit on key NASH mechanisms
BioCentury | Sep 6, 2019
Company News
Management tracks: Prometheus, Step, Spero, NorthSea, Aristea, MODAG and more
BioCentury | Jul 13, 2018
Finance
Forbion builds immunity
Forbion’s fourth fund bumps up biotech allocation and continues to build newcos
Items per page:
1 - 9 of 9